And four other potential targets that could make sense for the beleaguered group.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
The registrational Spearhead-1 trial of afami-cel backs up the efficacy seen in phase 1, without some of the related toxicities.
Key catalysts approach for Orphazyme, Gemini and Immutep.
First signals of efficacy, at doses thought to have been sub-therapeutic, send the Spac-listed group up 30%.